Aquablation Therapy is a minimally invasive robotic surgical technique to treat benign prostatic hyperplasia (BPH).
Aquablation therapy is a minimally invasive robotic surgical technique to treat benign prostatic hyperplasia (BPH).
Aquablation therapy is changing the tradeoff between symptom relief and side effects. Aquablation therapy uses a heat-free waterjet that precisely removes prostate tissue without the risk of side effects or complications caused by other heat-based treatments. Aquablation therapy is delivered by the AquaBeam® Robotic System, the world’s first commercially available autonomous tissue removal robot for the treatment of BPH.
In a large global clinical study, Aquablation therapy was proven to have less risk of side effects with similar symptom relief as the surgical gold standard transurethral resection of the prostate (TURP).
Aquablation therapy is approved for BPH patients suffering from lower urinary tract symptoms, regardless of prostate size.
Most side effects typically resolve within two to four weeks after the procedure. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder and bladder or urinary tract infection. Other risks include anejaculation (10%)1 and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment.
1. Gilling P. et al. “WATER - A Double-Blind Randomized Controlled Trial of Aquablation vs. TURP” J Urol. January 2018.